marketcaparena

Ascendis Pharma A/S

ASND · Figures in euros

About Ascendis Pharma

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.

ascendispharma.com ↗

Leadership

  • Scott Thomas SmithExecutive Vice President & Chief Financial Officer
  • Michael Wolff JensenExecutive Vice President, Chief Legal Officer
  • Anni Lotte Kirstine Sonderbjerg PedersenExecutive Vice President & Chief Admin Officer
  • Jay Donovan WuExecutive Vice President & President US Market
  • Aimee ShuExecutive Vice President & Chief Medical Officer
Employees
1,189
Business address
HELLERUP
Fiscal year ends
December 31
Listed
Nasdaq · ASND

Price

Share price

Daily closing price. The header shows the latest close, the market cap at that close and the change over the selected range. Hover or tap the chart to read any day.
$226.05
+$15.22 (+7.22%)past year
Market cap
$14B
At close
Oct 6, 2026

Share price vs index

Ascendis Pharma's share price and the index, each as its percentage change since the first day of the selected range. The shading shows the gap: green while Ascendis Pharma is ahead, orange while it is behind. The values at the end are each one's change over the range.

Revenue mix

Revenue by geography

FY25
Full year
Reported countries and regions in the chosen year or quarter. Known regions use standard geographic footprints. Hover shows the reported region total, never an allocation to individual countries. Ambiguous remainders are not mapped.

Geography growth

FY25
Year
Each country's or region's revenue in the chosen period against the same period a year earlier (YoY), so seasonal swings cancel out, or against the quarter before (QoQ). A year is always compared with the year before. Hover or tap a line to bring it forward.

Top geographies

FY25
Full year
Reported countries and regions in the chosen year or quarter, largest first, in the map's colours. The share of the disclosed geography shows only where the reported parts add up.

Income statement

Revenue, gross profit and net income

FY25
Full year
Revenue, gross profit and net income on one scale, so their sizes can be compared period by period.

Income statement

FY25
Full year
How revenue becomes net income in the chosen year or quarter. Solid bars are totals; hatched bars are the costs taken off between them.
TotalSubtracted

Operating leverage

FY25
Full year
Revenue growth against operating expense growth, each against the same quarter a year earlier. While revenue grows faster than opex, each extra dollar of sales keeps more profit.

Cash flow

Operating and free cash flow

FY25
Full year
Free cash flow is what is left of operating cash flow after capital expenditure. The gap between each pair of bars is that year's capex.

Cash flow statement

FY25
Full year
The reported movements behind the change in cash in the chosen year or quarter. Solid bars are totals; hatched bars are what was added or taken off between them.
TotalAddedSubtracted

Capital allocation

FY25
Full year
Operating cash flow above zero; what it was spent on below: capital expenditure, dividends and buybacks.

Stock-based compensation

FY25
Full year
Stock-based compensation reported in the cash flow statement each period. The line is that amount as a percentage of the same period's revenue.
Stock-based compensation% of revenue

Balance sheet

Assets, liabilities and equity

Q4 25
Full year
Quarter
The balance sheet at the end of the chosen year or quarter. What the company owns on the left, against what it owes and what belongs to shareholders on the right. Both columns add up to total assets.

Net cash

Q4 25
Full year
Quarter
Cash and short-term investments minus total debt at each quarter end. Below zero, the company owes more than it holds.
Net cashNet debt

War chest

Q4 25
Full year
Quarter
Cash and short-term investments held at each quarter end. The figure at the top of each column is the total.